<DOC>
	<DOCNO>NCT01640444</DOCNO>
	<brief_summary>The purpose study explore influence BRAF PIK3K status efficacy FOLFIRI plus Bevacizumab Cetuximab , first line therapy patient RAS wild-type metastatic colorectal carcinoma &lt; 3 circulate tumor cell</brief_summary>
	<brief_title>Influence BRAF PIK3K Status Efficacy 5-Fluorouracil/Leucovorin/Oxaliplatin ( FOLFIRI ) Plus Bevacizumab Cetuximab Patients With RAS Wild-type Metastatic Colorectal Carcinoma &lt; 3 Circulating Tumor Cells ( CTC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patient 's Informed consent write . 2 . Age 1870 year old . 3 . ECOG 01 . 4 . Life expectancy least 3 month . 5 . Histological confirmation adenocarcinoma colon rectum . 6 . Sample tumour tissue available evaluation gene RAS , BRAF PI3K . To include study patient present &lt; 3 CTC peripheral blood RAS wildtype present sample tumor tissue . 7 . Measurable metastatic stage IV disease least 1 measurable metastatic lesion follow RECIST criterion v 1.1 ( non suitable radical surgery inclusion time ) . 8 . Prior radiotherapy allow must complete least 4 week randomization ( applicable ) . 9 . Adequate bone marrow , liver renal function . 10 . Women childbearing potential must negative serum urine pregnancy test . Postmenopausal woman must amenorrheic least 12 months.Both men woman participate study must use adequate contraception . 11 . Subject must ability , opinion investigator , comply study procedure followup examination . 1 . Previous chemotherapy metastatic disease . 2 . Prior treatment Bevacizumab , EGFR inhibitors 3 . Any anticancer treatment ( chemotherapy , hormonal treatment , radiation treatment , surgery , immunotherapy , biologic therapy tumour embolization ) within 4 week randomization . 4 . Use investigational drug within 4 week start treatment . 5 . Clinical radiographic evidence brain metastasis . 6 . Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg and/or diastolic blood pressure &gt; 100 mmHg repeat measurement ) despite optimal medical management . 7 . Previous history hypertensive encephalopathy hypertensive crisis . 8 . Current history peripheral neuropathy &gt; equal 1 NCICTCAE . 9 . Patients classify fragile accord criterion list protocol . 10 . Significant cardiovascular disease ( e.g . AVC , myocardial infarction , within 6 month randomization ) . Unstable angina , congestive heart failure New York Heart Association ( NYHA ) â‰¥ class II , arrhythmia require treatment within 3 month randomization . 11 . Significant vascular disease ( e.g . aortic aneurism require surgical intervention , pulmonary embolic , peripheral arterial thrombosis ) within 6 month randomization . 12 . Previous history significant haemorrhage /severe , within 1 month randomization . 13 . Major surgery , open surgical biopsy significant traumatic injury within 4 week randomization . 14 . Large bore needle biopsy major organ within 14 day randomization . Placement central venous access port &gt; equal 7 day randomization permit . 15 . Evidence history bleed diathesis coagulopathy . 16 . INR &gt; 1.5 within 14 day prior start study treatment . EXEMPTION : patient full anticoagulation must inrange INR [ usually 23 ] . Any anticoagulation therapy must stable dose prior enrolment . 17 . History previous abdominal fistula gastrointestinal perforation within 6 month randomization . 18 . Serious nonhealing wound , ulcer bone fracture . 19 . Acute subacute intestinal occlusion history intestinal inflammatory disease . 20 . History uncontrolled convulsive crisis . 21 . History pulmonary fibrosis , acute lung disease interstitial pneumonia . 22 . Chronic , actual recent use ( 10 day prior first drug administration ) acetylsalicylic acic ( aspirin ) &gt; 325 mg/day clopidogrel ( 75mg/day ) treatment cause gastrointestinal ulcer ( lowdose aspirin permit &lt; equal 325 mg/day ) . 23 . Urinary protein excretion &gt; equal 2+ ( dipstick ) . If &gt; equal 2 g proteinuria detect dipstick , 24hour period urine test perform result &lt; equal 1 g/24 hour permit inclusion patient clinical trial 24 . Known human immunodeficiency virus infection chronic hepatitis B C infection uncontrolled , severe concurrent infection . 25 . Current infection &gt; equal Grade 2 ( NCICTCAE ) . 26 . Any previous concurrent cancer different colorectal carcinoma within 5 year start treatment . Subjects successfully treat , noninvasive cancer , include cervical cancer situ , basal cell carcinoma allow participate clinical trial . Or cancer treat curative intention without disease evidence last 5 year least 27 . Known suspected allergy hypersensitivity component bevacizumab , cetuximab , irinotecan , 5FU/LV . 28 . Any medical , psychological , social condition may interfere subject 's participation study evaluation study result . 29 . Any psychological , familial geographic situation interfere adequate followup adherence study protocol . 30 . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>colorectal carcinoma</keyword>
	<keyword>BRAF PIK3K</keyword>
	<keyword>FOLFIRI -Bevacizumab -Cetuximab</keyword>
	<keyword>circulate tumor cell</keyword>
</DOC>